H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Beyondspring Inc (NASDAQ: BYSI) today and set a price target of $60. The company’s shares closed yesterday at $26.50.
Pantginis said:
“Valuation and risks to price target achievement. We maintain our Buy rating with a $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -9.6% and a 35.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Beyondspring Inc is Moderate Buy and the average price target is $54, representing a 103.8% upside.
In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Based on Beyondspring Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $15.49 million. In comparison, last year the company had a GAAP net loss of $47.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
